Domestic pharmaceutical companies have challenged the hemophilia treatment market one after another. JW Pharma released Hemlibra and SK Plasma released Afstyla in the last year.

The domestic hemophilia treatment market is maintained by GC Pharma and Takeda. While Bayer, Sanofi, and Pfizer, which have challenged the market in the past, are struggling, attention is focusing on whether domestic pharmaceutical companies will produce meaningful results.

◆GC Pharma is virtually monopolizing the domestic market with a size of ₩230 billion

According to the pharmaceutical industry on the 30th, SK Plasma started selling Afstyla to major general hospitals in South